Investing.com - Financial Markets Worldwide

JMP reiterates Market Outperform rating on Rapport Therapeutics stock

Published 16/07/2025, 10:06
JMP reiterates Market Outperform rating on Rapport Therapeutics stock
RAPP
1.42%

Investing.com - JMP Securities maintained its Market Outperform rating and $28.00 price target on Rapport Therapeutics (NASDAQ:RAPP), currently valued at $524.84 million, following a key opinion leader (KOL) call. According to InvestingPro data, analyst targets range from $28 to $42, with a strong consensus recommendation of 1.2 (Strong Buy).

The firm expressed increased confidence in potential positive Phase 2 results for RAP-219 in focal epilepsy, expected in September.

JMP recently hosted Dr. Vikram Rao, a neurologist from UCSF and epilepsy specialist, to discuss the upcoming proof-of-concept results for the company’s lead drug candidate.

According to JMP, Dr. Rao expressed optimism about RAP-219’s potential in focal epilepsy, citing its validated yet differentiated mechanism of action, compelling preclinical results, and innovative Phase 2 trial design.

Rapport Therapeutics remains one of JMP’s two high-conviction calls ahead of the September Phase 2 readout.

In other recent news, Rapport Therapeutics has been the focus of several analyst updates and discussions regarding its ongoing clinical trials. Citizens JMP reiterated its Market Outperform rating on Rapport Therapeutics, with a price target of $28, highlighting the upcoming Phase 2a trial results for RAP-219 in adults with refractory focal epilepsy as a potential catalyst. TD Cowen also maintained its Buy rating after hosting an investor dinner with a key opinion leader in epileptology, who expressed optimism about the trial design and the drug’s potential for improved tolerability. Jones Trading analysts reiterated their Buy rating with a price target of $42, following the company’s Investor & Analyst Day, where expectations for successful trial outcomes were discussed. Stifel analysts have also reiterated their Buy rating, maintaining a $35 price target, and noted a high concordance rate between long episodes and EEG seizures in the RAP-219 study. These developments reflect the continued positive sentiment among analysts regarding Rapport Therapeutics’ research and development efforts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.